Patents Examined by Irina Neagu
  • Identification of compounds that disperse TDP-43 inclusions
    Patent number: 9359363
    Abstract: Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: June 7, 2016
    Assignees: AQUINNAH PHARMACEUTICALS, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Wolozin, Marcie Glicksman, Gregory D. Cuny, Justin Boyd
  • Topical skin care composition
    Patent number: 9333172
    Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: May 10, 2016
    Assignee: GALDERMA S.A.
    Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
  • Compositions and methods for treating tuberculosis
    Patent number: 9333193
    Abstract: The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: May 10, 2016
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Paul S. Hoffman, Timothy L. MacDonald, Eric R. Houpt, Thomas E. Ballard, Jr.
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9328067
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 3, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
    Patent number: 9328071
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: May 3, 2016
    Assignee: SANOFI
    Inventors: Matthias Schaefer, Josef Pernerstorfer, Dieter Kadereit, Hartmut Strobel, Werngard Czechtizky, L. Charlie Chen, Alena Safarova, Aleksandra Weichsel, Marcel Patek
  • Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
    Patent number: 9320724
    Abstract: A method of improving cognition in a patient with Down syndrome, which entails administering one or more ?2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 26, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ahmad Salehi, Brian Mediana, Sarah Moghadam, Van Dang, Devsmita Das, Kara Martin
  • Efficient stabilizer in controlling self accelerated decomposition temperature of peroxycarboxylic acid compositions with mineral acids
    Patent number: 9288992
    Abstract: Highly acidic, stabilized peroxycarboxylic acid compositions are disclosed as having both improved antimicrobial efficacy in comparison to conventional peroxyoctanoic acid and peroxyacetic acid compositions for sanitizing applications, and improved transport and shipping stability. In particular, low odor and low/no VOC compositions having dual functionality as both acid wash and sanitizing compositions are disclosed.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: March 22, 2016
    Assignee: Ecolab USA, Inc.
    Inventors: Junzhong Li, David D. McSherry, Richard Staub
  • Processes for preparing isoquinolinones and solid forms of isoquinolinones
    Patent number: 9290497
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: March 22, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes
    Patent number: 9278920
    Abstract: Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C0-4)alkyl-hydroxy-cycloalkyl- or bicycloalkylsulfanyl)-acetyl]-mutilins which are 14-O-[(amino(C0-4)alkyl-hydroxy-cyclobutylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclopentylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cycloheptylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclooctylsulfanyl)-acetyl]-mutilins, or 14-O-[(amino(C0-4)alkyl-hydroxy-bicycloalkylsulfanyl)-acetyl]-mutilins, optionally in the form of a salt and/or a solvate, a pharmaceutical compositions comprising such compounds and their use as pharmaceuticals, e.g. for the treatment of microbial infections and for the treatment of acne, optionally in combination with other pharmaceutically active agents.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: March 8, 2016
    Assignee: Nabriva Therapeutics AG
    Inventors: Rosemarie Riedl, Klaus Thirring, Werner Heilmayer
  • Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof
    Patent number: 9271961
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • Sanglifehrin derivatives and methods for their production
    Patent number: 9271977
    Abstract: There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: March 1, 2016
    Assignee: NeuroVive Pharmaceutical AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Steven Gary Kendrew, Christine Janet Martin
  • Carbazole-containing sulfonamides as cryptochrome modulators
    Patent number: 9265772
    Abstract: The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: February 23, 2016
    Assignee: RESET THERAPEUTICS, INC.
    Inventors: Ross Bersot, Paul Humphries
  • Biotherapeutics for the treatment of infectious diseases
    Patent number: 9254330
    Abstract: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: February 9, 2016
    Assignee: Biological Responsibility, LLC
    Inventor: Gordon Chiu
  • 1,4 oxazines as BACE1 and/or BACE2 inhibitors
    Patent number: 9242943
    Abstract: The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: January 26, 2016
    Assignees: SIENA BIOTECH S.P.A., HOFFMANN-LA ROCHE INC.
    Inventors: Matteo Andreini, Emanuele Gabellieri, Wolfgang Guba, Hans Hilpert, Alexander V. Mayweg, Robert Narquizian, Eoin Power, Massimiliano Travagli, Thomas Woltering, Wolfgang Wostl, Harald Mauser
  • Sulfamides as TRPM8 modulators
    Patent number: 9233947
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: January 12, 2016
    Assignee: Janssen Pharmaceutica, NV
    Inventor: Jay M Matthews
  • Fused cyclooctyne compounds and their use in metal-free click reactions
    Patent number: 9222940
    Abstract: The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 29, 2015
    Assignee: SynAffix B.V.
    Inventors: Floris Louis Van Delft, Floris Petrus Johannes Theodorus Rutjes, Frederik Jan Dommerholt
  • Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof
    Patent number: 9212196
    Abstract: The invention relates to hypophosphorous acid derivatives of formula (I) wherein —X is H or OH, —R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl group, one to four of R1-R5 being H and the others being selected in the group comprising -0-(CH2)n—COOH; —S—(CH2)n—COOH; —NH—(CH2)n—COOH; -0-(CH,R?)—COOH; —O—(CH2)n—OH; OR?, —R? being a C1-C3 alkyl radical; —OH; —COOH; halogen, particularly —F, —CI, —Br, —I, —CF3; —OCF3; —N02; —CH?CH—COOH; —(CH2)n—COOH; O—(CH2)n—P03H2; O—(CF2)n—P03H2; O—(CH2)n—S03H; O—(CH2)n—CONHOH; O—(CH2)n-tetrazol; O—(CH2)n-hydroxyisoxazol—n=1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: December 15, 2015
    Assignees: UNIVERSITE PARIS DESCARTES, UNIVERSITE D'AUVERGNE
    Inventors: Francine Acher, Jean-Philippe Pin, Cyril Goudet, Alain Eschalier, Jérôme Busserolles, Delphine Rigault, Isabelle Lemasson, Sara Cesarini, Bruno Commare
  • Inhibitors of viral entry into mammalian cells
    Patent number: 9212134
    Abstract: The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 15, 2015
    Assignee: Microbiotix, Inc.
    Inventors: Arnab Basu, Debra M. Mills, John D. Williams, Bing Li, Norton P. Peet, Terry L. Bowlin
  • Methods and devices for using isoperillyl alcohol
    Patent number: 9211269
    Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: December 15, 2015
    Assignee: NEONC TECHNOLOGIES INC.
    Inventors: Thomas Chen, Daniel Levin, Satish Pupalli, Daniel A Dickman
  • Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
    Patent number: 9193732
    Abstract: This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Novartis AG, Astex Therapeutics, LTD
    Inventors: John Vincent Calienni, Guang-Pei Chen, Baoqing Gong, Prasad Koteswara Kapa, Vishal Saxena